MedTrace Logo

CyberKnife for Prostate Cancer Patients Aged 70 y or More

NCT03235557 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2022-06-22

No results posted yet for this study

Summary

Robotic Stereotactic Radiation treatment of prostatic adenocarcinoma of the elderly.

Inclusion criteria : T1-T3b, MRI pelvic nodes negative, M0, any Gleason Score, PSA (Prostate Specific Antigen) \<30ng/ml.

Dose : 36.25 Gy in 5 fractions, in 10 days, considering CAPRA Scores≤5 AND 37.5 Gy in 5 fractions, in 10 days, considering CAPRA Scores\>5.

Primary objective : acute and late toxicity evaluation at 36 months. Secondary objectives : PSA and MRI response.

Conditions

Sponsors & Collaborators

  • Centre Francois Baclesse, Luxembourg

    lead OTHER

Principal Investigators

  • Philippe Nickers, MD, PhD · Centre Francois Baclesse

  • Michel Untereiner, MD · Centre Francois Baclesse

Eligibility

Min Age
70 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2018-10-31
Completion
2021-12-31

Countries

  • Luxembourg

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03235557 on ClinicalTrials.gov